SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Passive Stake in Bio-Path Holdings

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a beneficial ownership of 4.99% of Bio-Path Holdings, Inc.'s common stock as of March 31, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in BIO-PATH HOLDINGS, INC.
• As of March 31, 2025, the Reporting Persons collectively beneficially own 436,337 shares of Bio-Path Holdings, Inc.'s Common Stock, par value $0.001 per share.
• This ownership represents 4.99% of the total outstanding class of securities.
• The Reporting Persons hold shared voting power and shared dispositive power over all 436,337 shares.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, is deemed to beneficially own the securities held by the Master Fund.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The sentiment is neutral. A Schedule 13G filing is a routine regulatory disclosure. While the 4.99% stake implies a reduction from a previous filing (as it's an amendment), it's a passive stake and not indicative of strong positive or negative sentiment towards the company's operational performance.

Positives

• The filing indicates that a significant institutional investor, Armistice Capital, maintains a substantial stake in Bio-Path Holdings, Inc., suggesting continued interest in the company.
• The nature of the filing (Schedule 13G) confirms that the stake is passive and not intended for control, which can reduce concerns about potential activist interventions.

Negatives

• The beneficial ownership percentage of 4.99% is just below the 5% threshold, which typically indicates a reduction in stake from a previous filing (as this is Amendment No. 1) or a decision to remain passive, potentially signaling a less aggressive investment stance.
• A reduction in stake, even if minor, could be interpreted by some investors as a slight decrease in the investor's conviction or a strategic portfolio rebalancing.

Risks

• The reduction in stake below the 5% threshold might be interpreted by the market as a slight decrease in the investor's conviction or a strategic portfolio adjustment, which could influence investor sentiment.

Future Outlook

This Schedule 13G filing is a historical report of beneficial ownership and does not contain any forward-looking statements or guidance regarding the issuer's future performance or the reporting persons' future investment intentions beyond their passive holding purpose.

Industry Context

This filing is a routine disclosure of an institutional investor's passive equity stake in a publicly traded biotechnology company. It does not provide specific insights into broader industry trends but reflects an investor's position within the healthcare or pharmaceutical sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception. The slight reduction in stake below the 5% threshold might lead to questions about the investor's long-term conviction or portfolio strategy.

Key Dates

Keywords

BIO-PATH HOLDINGS, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, investment management, institutional investor, equity stake